ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
Avatar

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

By ASH 2022 Conference Coverage FEATURING Kerry Rogers
By ASH 2022 Conference Coverage FEATURING Kerry Rogers
147 views
January 4, 2023
Comments 1
Login to view comments. Click here to Login
Leukemia
10:42

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in…

ASH 2022 Conference Coverage

J. Brown

203 views
05:06

ASH 2022 Ponatinib & Blinatumomab for Patients With R/R Ph+ ALL or C…

ASH 2022 Conference Coverage

W. Macaron

73 views
03:41

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

ASH 2022 Conference Coverage

G. Borthakur

180 views
11:00

ASH 2022 Updates and Highlights in CML

ASH 2022 Conference Coverage

E. Atallah

126 views
14:41

Clinical Implications of the QUAZAR AML-001 Trial: Oral AZA Maintena…

ASH 2022 Conference Coverage

P. Michael

230 views
19:04

ASH 2022: Real-World Comparison of Time to Next Treatment for Patien…

ASH 2022 Conference Coverage

R. Jacobs

133 views
07:16

CAPTIVATE Study Updates: CLL Treatment Outcomes After Undetectable M…

ASH 2022 Conference Coverage

C. Tam

152 views
14:37

ASH 2022 Results of the ASC4MORE Study: Asciminib Add-On to Imatinib…

ASH 2022 Conference Coverage

G. Saglio

90 views
11:30

ASH 2022 Post-Allogeneic Stem Cell Transplant Outcomes in Patients T…

ASH 2022 Conference Coverage

A. Jain

380 views
06:57

ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targe…

ASH 2022 Conference Coverage

A. Danilov

39 views
13:16

Experts Discuss Key Updates in CLL

ASH 2022 Conference Coverage

S. O'Brien, C. Coombs

912 views
10:41

ASH 2022 Triplet Combination of Azacitidine, Venetoclax, and Gilteri…

ASH 2022 Conference Coverage

N. Short

513 views
06:22

ASH 2022 The Addition of Inotuzumab Ozogamicin to Hyper-CVAD + Blina…

ASH 2022 Conference Coverage

N. Short

149 views
07:38

ASH 2022 Ponatinib & Blinatumomab for Pts With Newly Diagnosed Ph+ A…

ASH 2022 Conference Coverage

N. Short

39 views
11:05

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Study o…

ASH 2022 Conference Coverage

D. DeAngelo

21 views
09:45

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outco…

ASH 2022 Conference Coverage

K. Rogers

147 views
11:10

ASH 2022 Updated Phase 2b Results of Venetoclax With FLAG-IDA in R/R…

ASH 2022 Conference Coverage

M. Konopleva

342 views
08:14

ASH 2022 Single vs. Double Induction With "7+3" Containing 60 vs. 90…

ASH 2022 Conference Coverage

C. Röllig

196 views
07:48

ASH 2022 Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Fe…

ASH 2022 Conference Coverage

C. Röllig

101 views
27:09

ASH 2022: What Is Complete HLA Match in 2022?

ASH 2022 Conference Coverage

S. Spellman

196 views
11:12

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic…

ASH 2022 Conference Coverage

J. Miller

82 views
08:00

ASH 2022 Phase III ASAP Trial Results: Sequential Conditioning & Imm…

ASH 2022 Conference Coverage

J. Schetelig

71 views
15:43

ASH 2022 UK NCRI AML19 Trial: FLAG-Ida With Gemtuzumab Ozogamicin Im…

ASH 2022 Conference Coverage

N. Russell

93 views
20:03

ASH 2022: Post-Remission Outcomes in Patients With AML Are Similar B…

ASH 2022 Conference Coverage

M. Hochman

190 views
09:54

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

ASH 2022 Conference Coverage

A. Hoover

34 views
07:05

ASH 2022: Lintuzumab-Ac225 in Combination With Intensive Chemo Yield…

ASH 2022 Conference Coverage

S. Abedin

51 views
10:28

ASH 2022 Phase 1 Study With the Novel Bcl-2 Inhibitor BGB-11417 as M…

ASH 2022 Conference Coverage

C. Cheah

47 views
06:20

Consolidation With Allogeneic HCT Improved Survival Outcomes of Adul…

ASH 2022 Conference Coverage

I. Aldoss

73 views
16:32

ASH 2022 Phase 3 GLOW Study: Residual Disease Kinetics Among CLL Pat…

ASH 2022 Conference Coverage

C. Utoft Niemann

55 views
04:07

ASH 2022 Novel Combination of Clinical Menin Inhibitor Ziftomenib an…

ASH 2022 Conference Coverage

S. Balasubramanian

137 views
09:33

ASH 2022 4-Year Follow-up Data on Combined Ibrutinib and Venetoclax …

ASH 2022 Conference Coverage

N. Jain

201 views
05:38

ASH 2022 Preclinical In Vivo Activity of the Menin Inhibitor Ziftome…

ASH 2022 Conference Coverage

S. Tasian

68 views
06:23

ASH 2022 Comparing Venetoclax & Azacitidine to Conventional Inductio…

ASH 2022 Conference Coverage

A. Fathi

800 views
06:04

ASH 2022 Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibruti…

ASH 2022 Conference Coverage

S. Stilgenbauer

38 views
05:12

ASH 2022 Asciminib as Initial Therapy for Patients With CML-CP: H. J…

ASH 2022 Conference Coverage

E. Atallah

97 views
09:42

Transplant in AML With MRD: Proceed or Defer?

ASH 2022 Conference Coverage

C. Craddock

354 views
15:42

ASH 2022: Reduced Venetoclax Exposition to 7 Days of Azacitidine Is …

ASH 2022 Conference Coverage

C. Willekens

599 views
07:37

ASH 2022: More Than 10 Years Follow-Up of Frontline TKI Therapy in P…

ASH 2022 Conference Coverage

F. Haddad

220 views
07:41

ASH 2022 Effectiveness of TKIs in Patients With CML-CP After Two or …

ASH 2022 Conference Coverage

D. Žáčková

105 views
08:19

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolerabili…

ASH 2022 Conference Coverage

N. Shah

349 views
08:12

ASH 2022 Final Analysis Results From the InformCLL Registry: Real-Wo…

ASH 2022 Conference Coverage

N. Ghosh

37 views
11:38

ASH 2022 ECOG-ACRIN-E1910 Randomized Phase III NCTN Trial: Blinatumo…

ASH 2022 Conference Coverage

M. Litzow

119 views
07:30

ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Symptomat…

ASH 2022 Conference Coverage

E. Padron

55 views
08:00

ASH 2022 Contemporary Guidelines for Diagnosis and Genomic Classific…

ASH 2022 Conference Coverage

I. Iacobucci

55 views
08:02

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

ASH 2022 Conference Coverage

S. Holtan

355 views
04:55

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

ASH 2022 Conference Coverage

E. Stein

168 views
11:52

ASH 2022 Real-World OS and TTNT by 1L Therapy (BTKi and BCL2i) in Pa…

ASH 2022 Conference Coverage

W. Archibald, C. Wang

119 views
05:33

ASH 2022: Phase II Study of Inotuzumab Ozogamicin for the Treatment …

ASH 2022 Conference Coverage

J. Senapati

64 views
10:39

ASH 2022: Splicing Factor Gene Mutations Do Not Affect Outcomes in N…

ASH 2022 Conference Coverage

J. Senapati

34 views
07:43

ASH 2022 The Menin Inhibitor Revumenib (SNDX-5613) Leads to Durable …

ASH 2022 Conference Coverage

G. Issa

121 views
08:57

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

ASH 2022 Conference Coverage

J. Bewersdorf

97 views